Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

摘要

The combination of undetectable HCV viral load and magnitude of decline at week 4 has a high PPV for SVR and identified a higher number of potential Peg-IFN/RBV responders.